The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Lin Zhou
No relevant relationships to disclose
Jin Li
No relevant relationships to disclose
Ding-Lun Ai
No relevant relationships to disclose
Junliang Fu
No relevant relationships to disclose
Xiao-Ming Peng
No relevant relationships to disclose
Lin-Zhi Zhang
No relevant relationships to disclose
Yun Zhao
No relevant relationships to disclose
Jing-Yan Wang
No relevant relationships to disclose
Qiang Yu
No relevant relationships to disclose
Chun-Zi Liu
No relevant relationships to disclose
Wei Ma
No relevant relationships to disclose
Hua-Ming Wang
No relevant relationships to disclose